Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1293 participants.
Also called NCT03794336
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,293 participants
- Sponsor
- Registry
-
NCT03794336
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03794336. Randomized; no masking; primary purpose treatment. Start 2019-06-29 (actual); primary completion 2020-12-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Acronym
- ACADEMIC
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Alogliptin
- Intervention (Drug)
- Acarbose
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03794336- Content hash
146352b818fe03137f75ab3147f5f44b2a45201df1053814bd3b9c79f3b23c3c